Malaria

Ginkgo Bioworks and SaponiQx Awarded MCDC Contract to Discover and Manufacture Next-Generation Vaccine Adjuvants Using Generative Molecular Design

Retrieved on: 
Thursday, February 15, 2024

Adjuvants are components of vaccines that help to enhance the magnitude, breadth, and duration of the immune response to vaccination.

Key Points: 
  • Adjuvants are components of vaccines that help to enhance the magnitude, breadth, and duration of the immune response to vaccination.
  • Currently, only a handful of adjuvants are available for human use in licensed vaccines.
  • Ginkgo will develop a first-generation Adjuvant Development Candidate (ADC) production method, using a heterologous production strain such as brewers' yeast, Saccharomyces cerevisiae.
  • Development of a first-generation ADC production method could facilitate further development of a sustainable mass-production manufacturing process for these complex adjuvants.

OscarⓇ-Nominated Documentary BOBI WINE: THE PEOPLE’S PRESIDENT Returns to Theaters President’s Day Weekend for Limited Run

Retrieved on: 
Wednesday, February 14, 2024

Museveni has been in power since 1986 and changed Uganda’s constitution to enable him to run for yet another five-year term.

Key Points: 
  • Museveni has been in power since 1986 and changed Uganda’s constitution to enable him to run for yet another five-year term.
  • More recently, the film was nominated for Best Documentary at the 96th Academy Awards.
  • It was awarded the prestigious Best Documentary Feature Award by the International Documentary Association (IDA).
  • The following theaters will be showing BOBI WINE: THE PEOPLE’S PRESIDENT:
    New York - Firehouse: DCTV's Cinema for Documentary Film - Find showtimes here .

Global health research suffers from a power imbalance − decolonizing mentorship can help level the playing field

Retrieved on: 
Tuesday, February 13, 2024

Mentors, typically from the Global North, or high-income countries, are often seen as more credible than mentees who are mostly from the Global South.

Key Points: 
  • Mentors, typically from the Global North, or high-income countries, are often seen as more credible than mentees who are mostly from the Global South.
  • Hierarchical relationships, especially those between people from the Global North and Global South, are not mutually beneficial or fair.
  • Based on our personal experiences and research as public health researchers, statisticians and social scientists, we believe that cultural humility and equitable partnerships are key to effective global health projects.
  • Decolonizing mentorship in global health, or addressing the historical power imbalances between researchers from the Global North and Global South, can help advance global health for all.

Challenges in global health research

  • Some scholars have defined global health as “collaborate transnational research and action for promoting health for all.” Historically, however, the concept of global health is rooted in Western ideas of who is considered human.
  • This hierarchy is omnipresent in knowledge exchange and health resource allocation between the Global North and Global South.
  • Notably, most of the major global health institutes are located in the Global North, although the greatest burden of diseases such as HIV and malaria is centered in the Global South.
  • For example, several scholars from the Global South have noted how visa restrictions and fees affected their ability to attend global health conferences in high-income countries.

Decolonizing global health

  • For example, a researcher from the Global North may be more knowledgeable about a new technology, but a researcher from the Global South may know how best to adapt the technology locally.
  • Tailoring mentorship programs to address the specific needs of scholars in the Global South will also help cultivate a sense of inclusivity and belonging.
  • Establishing communication channels that accommodate various languages would allow scholars to be able to fully participate in the global health dialogue.
  • Decolonizing mentorship in global health is not a theoretical concept but an actionable strategy.
  • Addressing the unique challenges that researchers in the Global South face can help bridge the global health divide, allowing local scholars to actively shape the future of the field and their communities.


Oluwafemi Atanda Adeagbo receives funding from National Institutes of Health and University of Iowa Brenda Yankam and Engelbert Bain Luchuo do not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and have disclosed no relevant affiliations beyond their academic appointment.

On-Device AI Healthcare Company Noul Becomes First Korean Diagnostic Company to Join Swiss Malaria Group

Retrieved on: 
Monday, February 12, 2024

The recognition of innovation in the malaria diagnostic solution, miLab™ MAL played a major role in Noul becoming an official member of the Swiss Malaria Group.

Key Points: 
  • The recognition of innovation in the malaria diagnostic solution, miLab™ MAL played a major role in Noul becoming an official member of the Swiss Malaria Group.
  • Dr. Taehwan Kim, Managing Director of noul GmbH said, "noul GmbH will play a pivotal role in global malaria diagnosis through its activities as a member of the Swiss Malaria Group.
  • Swiss Malaria Group said, "Noul's innovative diagnostic tools align perfectly with the Swiss Malaria Group's emphasis on innovative solutions in the fight against malaria.
  • Noul, which focuses on diagnostic solutions in blood and tissue diagnostics, has developed a cutting-edge digital microscopy-based malaria diagnostic tool, miLab™ MAL."

AI in the developing world: how ‘tiny machine learning’ can have a big impact

Retrieved on: 
Thursday, February 8, 2024

The landscape of artificial intelligence (AI) applications has traditionally been dominated by the use of resource-intensive servers centralised in industrialised nations.

Key Points: 
  • The landscape of artificial intelligence (AI) applications has traditionally been dominated by the use of resource-intensive servers centralised in industrialised nations.
  • However, recent years have witnessed the emergence of small, energy-efficient devices for AI applications, a concept known as tiny machine learning (TinyML).

Small size, big impact

  • This is possible because TinyML doesn’t require a laptop computer or even a mobile phone.
  • In fact, given that there are already 250 billion microcontrollers deployed globally, devices that support TinyML are already available at scale.

How does it work?

  • Like classical machine learning, TinyML involves data collection – often from Internet of Things (IoT) devices – and cloud-based training.
  • Let’s consider an outdoor object-detection application – for example, counting the number of cars on a street to see how heavy the traffic there is.
  • In the classical ML process, images have to be gathered using a webcam and sent to a cloud server where the training takes place.


Affordability: the technology’s low cost makes these devices accessible to a wide range of users including educational institutions and students in the developing world.
Sustainability: the modest energy consumption produces a low carbon footprint, reducing impact on the environment.
Flexibility and scalability: it enables the development of applications that address the needs of local communities rather than global agendas.
Internet independent: Because everything is embedded, TinyML devices can operate without online connectivity. This is particularly beneficial for the third of the world that still does not have Internet access.
TinyML applications already power personalised sensors for athletics and provide localisation where GPS isn’t available. They’re also employed by startups such as Useful Sensors, which offers privacy-conserving conversational agents, QR code scanners, and person-detection hardware. Only through the use of TinyML could these smart devices run on the low-cost, low-power microcontrollers.

Developing in the Global South

  • It already includes more than 40 countries spanning the Global South from Columbia to Ethiopia to Malaysia.
  • Its aim is to develop a community of educators, researchers and practitioners focused on both improving access to TinyML education, and developing innovative solutions to address the unique challenges faced by developing countries.
  • Initial efforts included distributing TinyML hardware kits to selected universities with budgetary challenges.
  • We also organised global and regional (Africa, Latin America, and Asia) workshops and training sessions.
  • These collaborations have led to multiple peer-reviewed papers on TinyML applications.
  • They’re also used by Cornell University’s “Elephant Listening Project” as well monitoring water quality in aquaculture to help make it more sustainable, a project supported by EU’s Horizon 2020 programme.

Looking forward

  • It offers a sustainable path toward democratising AI technology, fostering local innovation, and addressing regional challenges.
  • The growth of TinyML devices and applications is not without potential challenges and risks, however.
  • There’s also the risk of embedded biases in critical ML models – because they operate standalone, there’s no option for updates.


Les auteurs ne travaillent pas, ne conseillent pas, ne possèdent pas de parts, ne reçoivent pas de fonds d'une organisation qui pourrait tirer profit de cet article, et n'ont déclaré aucune autre affiliation que leur organisme de recherche.

60 Degrees Pharmaceuticals Appoints Kristen Landon as Chief Commercial Officer

Retrieved on: 
Thursday, February 8, 2024

WASHINGTON, Feb. 08, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP ; SXTPW) (“60P” or the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, announced today it has appointed Kristen Landon to the newly created role of Chief Commercial Officer, effective immediately.

Key Points: 
  • WASHINGTON, Feb. 08, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP ; SXTPW) (“60P” or the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, announced today it has appointed Kristen Landon to the newly created role of Chief Commercial Officer, effective immediately.
  • Ms. Landon is an accomplished commercial leader with over 26 years’ experience launching, building, and transforming commercial teams and brands in the pharmaceutical industry.
  • “We screened hundreds of applicants during the second half of 2023 and Kristen’s vision and directly relevant experience made her the ideal match for the position,” said Geoff Dow, PhD., 60 Degrees Pharma Chief Executive Officer.
  • Ms. Landon holds an MBA from Silberman College of Business at Fairleigh Dickinson University, and a Bachelor’s degree from Kean University.

New International Samaritan partnership takes Trinity Health doctors and residents to Ethiopia

Retrieved on: 
Tuesday, February 6, 2024

ANN ARBOR, Mich., Feb. 6, 2024 /PRNewswire/ -- In a new partnership with International Samaritan, a select group of Trinity Health doctors and residents will be traveling to care for patients at a hospital in Addis Ababa, the capital city of Ethiopia, as part of the Trinity Health Ann Arbor residency program.

Key Points: 
  • ANN ARBOR, Mich., Feb. 6, 2024 /PRNewswire/ -- In a new partnership with International Samaritan, a select group of Trinity Health doctors and residents will be traveling to care for patients at a hospital in Addis Ababa, the capital city of Ethiopia, as part of the Trinity Health Ann Arbor residency program.
  • A team of Trinity Health doctors traveled with International Samaritan to Addis Ababa this past October to visit the area and explore the idea of a partnership for Trinity Health residents.
  • Along with working at Alert Hospital, during their rotation, the Trinity Health physicians and residents will spend a day caring for the people that International Samaritan works with.
  • "Sixty International Samaritan families underwent comprehensive check-ups when three generous doctors from Trinity Health visited last October," said Selam Kahsay, International Samaritan's Health and Wellness Specialist in Ethiopia.

Researchers at KFSH&RC & KAUST Discover Gene Responsible for Reproduction of the Most Dangerous Malaria Strain

Retrieved on: 
Monday, February 5, 2024

RIYADH, Saudi Arabia, Feb. 05, 2024 (GLOBE NEWSWIRE) -- In a major scientific breakthrough, a research team from King Faisal Specialist Hospital and Research Centre (KFSH&RC), in collaboration with King Abdullah University of Science and Technology (KAUST), working alongside researchers from the UK, the US, and India, discovered a vital gene instrumental in combating malaria. This gene, termed PfAP2-MRP, is essential in the replication process of Plasmodium falciparum, the parasite that causes the most lethal strain of malaria.

Key Points: 
  • This gene, termed PfAP2-MRP, is essential in the replication process of Plasmodium falciparum, the parasite that causes the most lethal strain of malaria.
  • Advanced laboratory techniques enabled the researchers to inhibit the PfAP2-MRP gene, revealing its critical role in the malaria parasite’s life cycle within red blood cells.
  • This inhibition significantly disrupts the parasite’s ability to reproduce, reducing the severity of the disease’s symptoms and curbing its spread.
  • This discovery is particularly impactful as it addresses Plasmodium falciparum malaria, which claims over half a million lives annually.

Eisai Commences Fully-Fledged Business Activities at Pharma Sales Subsidiary in South Africa

Retrieved on: 
Thursday, February 1, 2024

Commencement of Direct Sales Operations in Africa, and Establishment of Branch Office in Kenya

Key Points: 
  • Commencement of Direct Sales Operations in Africa, and Establishment of Branch Office in Kenya
    TOKYO, Feb 1, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that fully-fledged operations have begun at Eisai Pharmaceuticals Africa (Pty) Ltd ("Eisai South Africa"), a pharmaceutical sales subsidiary recently established in Johannesburg, South Africa, and direct sales operations and business activities have commenced in Africa.
  • Eisai South Africa is a wholly-owned subsidiary of Eisai.
  • Eisai South Africa has started sales and marketing activities directly for Lenvima and Fycompa from January 2024, as well as Halaven from February 2024.
  • Seeking solutions to these challenges in Africa, Eisai will continue its initiatives to deliver necessary medicines to the patients who need them through Eisai South Africa and Eisai Kenya.

60 Degrees Pharmaceuticals Announces Closing of $2.4 Million Public Offering

Retrieved on: 
Wednesday, January 31, 2024

WASHINGTON, Jan. 31, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals , Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharmaceuticals” or the “Company”), specialists in developing and marketing new medicines for the treatment and prevention of infectious diseases, announced today the closing of its public offering of 5,260,901 units (the “Units”) at a price to the public of $0.385 per Unit and 999,076 pre-funded units (the “Pre-Funded Units”) at a price to the public of $0.375 per Pre-Funded Unit.

Key Points: 
  • WASHINGTON, Jan. 31, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals , Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharmaceuticals” or the “Company”), specialists in developing and marketing new medicines for the treatment and prevention of infectious diseases, announced today the closing of its public offering of 5,260,901 units (the “Units”) at a price to the public of $0.385 per Unit and 999,076 pre-funded units (the “Pre-Funded Units”) at a price to the public of $0.375 per Pre-Funded Unit.
  • Each Unit consists of one share of common stock and one warrant exercisable for one share of common stock (the “Warrant”).
  • The Pre-Funded Warrants are immediately exercisable and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full.
  • The gross proceeds to the Company from the offering were approximately $2.4 million, before deducting underwriter fees and other offering expenses payable by the Company.